Acrivon Therapeutics’ (ACRV) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research report released on Wednesday,Weiss Ratings reports.

Separately, Oppenheimer decreased their target price on shares of Acrivon Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a research report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Acrivon Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Acrivon Therapeutics Price Performance

NASDAQ:ACRV opened at $1.83 on Wednesday. The firm’s fifty day moving average price is $1.51 and its 200 day moving average price is $1.44. Acrivon Therapeutics has a 1-year low of $1.05 and a 1-year high of $8.74. The firm has a market cap of $57.57 million, a price-to-earnings ratio of -0.81 and a beta of 1.80.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Wednesday, August 13th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.02. As a group, analysts expect that Acrivon Therapeutics will post -2.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new position in shares of Acrivon Therapeutics during the 2nd quarter worth $26,000. Nuveen LLC acquired a new position in shares of Acrivon Therapeutics during the 1st quarter worth $27,000. Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics during the 1st quarter worth $72,000. Wealthedge Investment Advisors LLC raised its stake in shares of Acrivon Therapeutics by 420.1% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 56,467 shares of the company’s stock worth $115,000 after buying an additional 45,610 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Acrivon Therapeutics during the 2nd quarter worth $126,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.